跳转至内容
Merck
CN

M5060

E-4031

≥98% (HPLC), lyophilized powder

别名:

N-[4-[[1-[2-(6-甲基-2-吡啶基)乙基]-4-哌啶基]羰基]苯基]甲磺酰胺 二盐酸盐

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式(希尔记法):
C21H27N3O3S · 2HCl
化学文摘社编号:
分子量:
474.44
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352207
MDL number:
Assay:
≥98% (HPLC)
Form:
lyophilized powder
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助


Quality Level

assay

≥98% (HPLC)

form

lyophilized powder

storage condition

desiccated

technique(s)

cell culture | embryo: suitable

color

white

solubility

H2O: soluble

storage temp.

−20°C

SMILES string

Cl.Cl.Cc1cccc(CCN2CCC(CC2)C(=O)c3ccc(NS(C)(=O)=O)cc3)n1

InChI

1S/C21H27N3O3S.2ClH/c1-16-4-3-5-19(22-16)12-15-24-13-10-18(11-14-24)21(25)17-6-8-20(9-7-17)23-28(2,26)27;;/h3-9,18,23H,10-15H2,1-2H3;2*1H

InChI key

ZQBNWMFBOSOOLX-UHFFFAOYSA-N

Application

E-4031 已用作:
  • 人类诱导多能干细胞衍生的心肌细胞(hiPSC-CMs)中的人类ether-a-go-go基因(hERG)阻断剂
  • 长QT综合征(LQTS)诱导的多能干细胞(iPSC)胚状体的IKr阻滞剂
  • 大鼠心室肌细胞中的IKr阻滞剂

Biochem/physiol Actions

E-4031是一种抗心律不齐药物,属于III类。它是一种甲磺酰苯胺化合物,可有效治疗心律不齐并调节心室纤颤。E-4031介导转基因长QT 1型(LQT1)兔的动作电位持续时间(action potential duration ,APD)延长。人类 ether-a-go-go相关基因(hERG)中的异亮氨酸突变消除了其与E-4031的相互作用。
E-4031可选择性封闭hERG K+通道。

Features and Benefits

该化合物在受体分类和信号转导手册的钾通道页面上有重点介绍。想要浏览手册的其他页面, 请单击此处


存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)



历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库



Dissociation of E-4031 from the HERG channel caused by mutations of an amino acid results in greater block at high stimulation frequency
Ishii K, et al.
Cardiovascular Research, 57(3), 651-659 (2003)
Masataka Fujiwara et al.
PloS one, 6(2), e16734-e16734 (2011-03-03)
Induced pluripotent stem cells (iPSCs) are novel stem cells derived from adult mouse and human tissues by reprogramming. Elucidation of mechanisms and exploration of efficient methods for their differentiation to functional cardiomyocytes are essential for developing cardiac cell models and
Susann Björk et al.
Frontiers in physiology, 8, 884-884 (2017-11-23)
Current cardiac drug safety assessments focus on hERG channel block and QT prolongation for evaluating arrhythmic risks, whereas the optogenetic approach focuses on the action potential (AP) waveform generated by a monolayer of human cardiomyocytes beating synchronously, thus assessing the



全球贸易项目编号

货号GTIN
M5060-.1MG04061834059493
M5060-1MG04061834059516
M5060-.5MG04061834059509